The business model of SI-BONE Inc is focused on developing minimally invasive surgical solutions for patients suffering from sacroiliac (SI) joint disorders. The company specializes in the design and manufacturing of medical devices, including the iFuse Implant System. SI-BONE's innovative approach involves utilizing advanced technology and expertise to address the biomechanical causes of SI joint dysfunction. By providing effective treatment options, SI-BONE aims to improve patients' quality of life and restore their mobility. As a leader in the field, SI-BONE Inc continues to prioritize research, innovation, and collaboration with healthcare professionals in order to offer cutting-edge solutions for SI joint disorders.

SI-BONE Inc is primarily active in the healthcare industry, specifically specializing in the development and commercialization of innovative medical devices for patients suffering from musculoskeletal disorders. The company focuses on providing minimally invasive, cutting-edge solutions for the diagnosis and treatment of conditions related to the sacroiliac joint. With their groundbreaking technology and dedication to improving patient outcomes, SI-BONE Inc has positioned itself as a leader in the healthcare sector, offering effective solutions for individuals in need of long-term relief from debilitating pain and discomfort.

The main competitors of SI-BONE Inc in the market are Zimmer Biomet Holdings Inc, Medtronic PLC, and NuVasive Inc.

SI-BONE Inc is a leading medical device company specializing in minimally invasive solutions for the treatment of sacroiliac (SI) joint dysfunction. Founded in 2008, SI-BONE has emerged as a pioneer in this field, revolutionizing the way SI joint pain is diagnosed and treated. The company's flagship product is the iFuse Implant System, which provides a durable and minimally invasive option for patients suffering from SI joint dysfunction. Backed by extensive clinical research and a commitment to innovation, SI-BONE Inc has quickly gained recognition as a trusted provider of SI joint solutions, improving the quality of life for countless patients worldwide.

SI-BONE Inc has achieved several significant milestones in their history. One noteworthy accomplishment is the FDA clearance of their iFuse Implant System, a minimally invasive surgical solution for sacroiliac joint fusion. This clearance allowed SI-BONE Inc to offer their innovative treatment to patients suffering from SI joint dysfunction. Additionally, the company went public in 2018, marking another milestone in their growth. SI-BONE Inc's dedication to research and development has led to advancements in medical technology and improved patient outcomes. They continue to make strides in the field of SI joint fusion and are committed to providing effective solutions for patients.

SI-BONE Inc is primarily present in the United States and Europe.

SI-BONE Inc represents a commitment to improving patient lives through innovative medical solutions. Their corporate philosophy revolves around providing minimally invasive technologies for the diagnosis, treatment, and management of musculoskeletal disorders. The company actively focuses on advancing the field of sacroiliac joint dysfunction (SIJD) treatment with their FDA-cleared iFuse Implant System, offering a comprehensive solution for patients suffering from SIJD. SI-BONE Inc values patient-centric care, clinical research, collaboration with healthcare professionals, and continuous innovation to enhance patient outcomes. With their dedication to addressing unmet medical needs and improving quality of life, SI-BONE Inc has emerged as a trusted leader in the field of musculoskeletal healthcare.

Analysts currently set an average price target of 25.91 USD for the SI-BONE stock (median: 25.50 USD), implying +45.9 % versus the latest price. The consensus is based on 16 analyst ratings.

SI-BONE Analyst Price Targets 2026

16 analysts currently rate the SI-BONE stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SI-BONE to generate revenue of 231.62 M USD and earnings per share of -0.44 USD.

SI-BONE Analyst Price Targets 2026

Converted at the current exchange rate, the SI-BONE share trades at 15.42 EUR (17.76 USD).

The SI-BONE share (SIBN) is listed on 3 stock exchanges, including: NASDAQ (SIBN), Frankfurt (2K3.F), München (2K3.MU).

SI-BONE Inc is a medical company specialized in the development and marketing of innovative medical products in the field of spinal surgery. The company was founded in 2008 and is headquartered in Santa Clara, California. SI-BONE Inc specializes in the treatment of degenerative spinal diseases, particularly chronic lower back pain caused by Sacroiliac Joint Dysfunction. This condition affects millions of people worldwide and can lead to significant limitations in daily life. The business model of SI-BONE Inc is based on the development and marketing of innovative medical products aimed at improving the effectiveness and efficiency of Sacroiliac Joint Fusion (SI Fusion). Through the development of new technologies and applications, the company has introduced numerous products that support both minimally invasive and traditional surgical procedures. The flagship product of SI-BONE Inc is the iFuse Implant System, which is considered the only approved method for Sacroiliac Joint Fusion. The iFuse Implant is a small, triangular implant that is inserted into the SI Joint and provides permanent fixation. The implant is made of titanium, known for its strength and biocompatibility. In addition to the iFuse Implant System, SI-BONE Inc also offers a variety of training programs and support services for surgeons and medical professionals. The company has established a comprehensive network of clinics and medical centers to facilitate access to its products and services and raise awareness of the effectiveness of Sacroiliac Joint Fusion. SI-BONE Inc has also built a strong presence in the global market and works closely with international distributors to distribute its products worldwide. The company has branches in Europe, the Middle East, Africa, Asia, and Latin America to meet the needs of its global customers. The business model of SI-BONE Inc benefits both patients and surgeons and medical professionals. By providing innovative medical products and support services, the company contributes to improving patients' quality of life and avoiding potentially irreversible damage to the spine.

The expected revenue of SI-BONE is 231.62 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of SI-BONE is -19.21 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of SI-BONE is currently -40.22. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the SI-BONE stock.

The price-to-sales ratio (P/S) of SI-BONE is currently 3.34. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the SI-BONE stock.

The Eulerpool Quality Score for SI-BONE is 4/10.

The ISIN of SI-BONE is US8257041090. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of SI-BONE is A2N7LY. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of SI-BONE is SIBN. The ticker symbol is used to trade SI-BONE shares on the stock exchange.

SI-BONE paid dividends every year for the past 0 years.

SI-BONE is assigned to the 'Health' sector.

The dividends of SI-BONE are distributed in USD.